Compare NPK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | PCRX |
|---|---|---|
| Founded | 1905 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 1.0B |
| IPO Year | 1994 | 2010 |
| Metric | NPK | PCRX |
|---|---|---|
| Price | $143.37 | $23.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 71.4K | ★ 497.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.99 | 0.07 |
| Revenue | $503,524,000.00 | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | N/A | $8.54 |
| P/E Ratio | ★ $144.91 | $318.71 |
| Revenue Growth | ★ 29.70 | 26.04 |
| 52 Week Low | $82.67 | $18.80 |
| 52 Week High | $149.86 | $27.64 |
| Indicator | NPK | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 45.79 |
| Support Level | $125.99 | $21.80 |
| Resistance Level | $147.83 | $24.20 |
| Average True Range (ATR) | 6.58 | 1.23 |
| MACD | 0.28 | -0.20 |
| Stochastic Oscillator | 90.43 | 21.31 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.